Texas Permanent School Fund Corp Has $3.13 Million Stock Holdings in Repligen Corporation $RGEN

Texas Permanent School Fund Corp grew its position in Repligen Corporation (NASDAQ:RGEN) by 36.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 25,141 shares of the biotechnology company’s stock after buying an additional 6,688 shares during the period. Texas Permanent School Fund Corp’s holdings in Repligen were worth $3,127,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in RGEN. Twin Tree Management LP bought a new position in Repligen during the first quarter worth about $29,000. Hantz Financial Services Inc. lifted its holdings in shares of Repligen by 2,663.6% during the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares in the last quarter. Center for Financial Planning Inc. lifted its holdings in shares of Repligen by 34.2% during the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 126 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Repligen in the 2nd quarter valued at approximately $104,000. Finally, Hilltop National Bank bought a new stake in Repligen during the 2nd quarter worth approximately $147,000. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 3.0%

Shares of NASDAQ:RGEN opened at $162.38 on Friday. The company’s 50-day moving average price is $157.09 and its two-hundred day moving average price is $135.84. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The stock has a market capitalization of $9.14 billion, a PE ratio of 8,123.06, a price-to-earnings-growth ratio of 3.55 and a beta of 1.11.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The company had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. During the same quarter last year, the company earned $0.43 EPS. Repligen’s revenue for the quarter was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on RGEN shares. Wells Fargo & Company upped their price target on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Monday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Tuesday, September 2nd. Jefferies Financial Group set a $160.00 target price on Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. Evercore ISI lifted their price target on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Finally, Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $177.92.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the sale, the director owned 100,743 shares in the company, valued at $15,804,561.84. This represents a 19.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Karen A. Dawes sold 275 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 49,657 shares of company stock valued at $7,721,077 in the last 90 days. 1.20% of the stock is currently owned by insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.